CompletedNCT02140151
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
PHASE1 · PHASE2 · 108 planned enrolment
- Countries listed
- 1
- Registry update
- August 25, 2022
Registry Intervention View
Ranibizumab 0.5mg
Trial registrations containing the exact intervention label Ranibizumab 0.5mg.
Exact registry label · Not reported
4 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
2 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
CompletedNCT02302989
Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration
PHASE1 · PHASE2 · 4 planned enrolment
- Countries listed
- 1
- Registry update
- August 28, 2018
CompletedNCT01948830
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
PHASE3 · 650 planned enrolment
- Countries listed
- 19
- Registry update
- April 17, 2017
CompletedNCT01926977
Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
PHASE1 · PHASE2 · 100 planned enrolment
- Countries listed
- 1
- Registry update
- March 3, 2016